Person who experienced the adverse event (patient)
| Event ID | CASE | I F COD | FOLL SEQ | IMAGE | EVENT DT | MFR DT | FDA DT | REPT COD | MFR NUM | MFR SNDR | AGE | AGE COD | GNDR COD | E SUB | WT | WT COD | REPT DT | OCCP COD | DEATH DT | TO MFR | CONFID | REPORTER COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6140975 | 6965856 | I | 6140975-6 | 20090206 | 20090317 | 20090331 | EXP | 2009000823 | OSI PHARMACEUTICALS | 66 | YR | M | N | 20090323 | MD | 20090207 | GREECE |
Drug(s) used by person
| Event ID | DRUG SEQ | ROLE COD | DRUGNAME | VAL VBM | ROUTE | DOSE VBM | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6140975 | 1011367921 | PS | ERLOTINIB (ERLOTINIB) (TABLET) (ERLOTINIB) | 2 | ORAL | (150 MG, QD FOR 12 DAYS, EVERY 21 DAYS), ORAL | N | D | 21743 | ||
| 6140975 | 1011409080 | SS | TAXOTERE | 1 | INTRAVENOUS | (160 MG, Q 21 DAYS), INTRAVENOUS |
Indications of drugs used
| Event ID | DRUG SEQ | INDI PT |
|---|---|---|
| 6140975 | 1011367921 | NON-SMALL CELL LUNG CANCER |
| 6140975 | 1011409080 | NON-SMALL CELL LUNG CANCER |
Outcome of event
| Event ID | OUTC COD |
|---|---|
| 6140975 | DE |
Reactions reported
| Event ID | PT |
|---|---|
| 6140975 | DYSPNOEA |
| 6140975 | PULMONARY EMBOLISM |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | RPSR COD |
|---|---|
| 6140975 | FGN |
| 6140975 | HP |
| 6140975 | SDY |
Therapies reported
| Event ID | DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|
| 6140975 | 1011367921 | 20090206 | |||
| 6140975 | 1011409080 | 20090130 | 20090207 |